Related Experiment Video

Updated: Aug 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Induced proximity-based therapeutics for advanced prostate cancer

John Ching1, Cindy H Chau2, William D Figg3,4

  • 1Clinical Pharmacology Program, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, US.

Npj Drug Discovery
|August 14, 2026
PubMed

Insights

Induced proximity therapeutics offer a novel strategy to target androgen receptor (AR) signaling in metastatic castration-resistant prostate cancer (mCRPC). These advanced approaches show promise in overcoming treatment resistance for mCRPC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) remains dependent on androgen receptor (AR) signaling.
  • Existing therapies targeting AR signaling often face resistance in mCRPC.

Purpose of the Study:

  • To review recent advancements in induced proximity strategies for targeting AR in mCRPC.
  • To explore the potential of event-driven pharmacology in overcoming AR-related resistance.

Main Methods:

  • Review of current literature on induced proximity-based therapeutics.
  • Analysis of mechanisms of action for AR-targeting induced proximity agents.
  • Discussion of preclinical and clinical data related to these strategies.

Main Results:

  • Induced proximity strategies represent a promising therapeutic modality for mCRPC.
  • These approaches leverage event-driven pharmacology to enhance AR degradation or inhibition.
  • Recent advances show potential for overcoming resistance to conventional AR-targeted therapies.

Conclusions:

  • Induced proximity-based therapeutics are emerging as a significant strategy in mCRPC treatment.
  • Further research and clinical evaluation are warranted to fully realize the potential of these novel agents.
  • Targeting AR signaling through induced proximity may offer new hope for patients with resistant prostate cancer.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.